Recommended Products
Assay
98%
reaction suitability
reaction type: solution phase peptide synthesis
mp
159-163 °C (lit.)
application(s)
peptide synthesis
storage temp.
2-8°C
SMILES string
Cl[H].COC(=O)[C@H](N)Cc1ccccc1
InChI
1S/C10H13NO2.ClH/c1-13-10(12)9(11)7-8-5-3-2-4-6-8;/h2-6,9H,7,11H2,1H3;1H/t9-;/m1./s1
InChI key
SWVMLNPDTIFDDY-SBSPUUFOSA-N
Looking for similar products? Visit Product Comparison Guide
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Journal of medicinal chemistry, 39(4), 929-936 (1996-02-16)
For further studies on the structural and conformational requirements of positions 2,3, and 7 in the bradykinin sequence, we replaced the proline residues by the more hydrophobic and conformationally restricted N-methyl-L- and D-phenylalanine (NMF). The biological activities of the new
Biotechnology progress, 27(6), 1554-1560 (2012-01-12)
The direct one-step synthesis of L-phenylalanine methyl ester in an organic-aqueous biphasic system using phenylalanine ammonia lyase (E.C.4.3.1.5, PAL) containing Rhodotorula glutinis yeast whole cells was reported earlier. We report here further optimization of this biotransformation using isolated PAL, when
Pharmaceutical research, 10(8), 1174-1180 (1993-08-01)
The kinetics of demethylation of aspartame and L-phenylalanine methyl ester were studied in aqueous solution at 25 degrees C over the pH range 0.27-11.5. The pseudo-first-order rate constant for aspartame was resolved into individual contributions from methyl ester hydrolysis and
Blood, 80(9), 2401-2405 (1992-11-01)
Phenylalanine methylester (PME), a lysosomotropic compound can be used to deplete monocytes and myeloid cells from peripheral blood and bone marrow (BM). The potential of PME for purging leukemic cells from BM was investigated using U937 and HL-60 cell lines
Biochimica et biophysica acta, 1758(3), 347-354 (2005-12-29)
Many promising therapeutics are currently awaiting their clinical application. Due to their low capability of cell membrane crossing, these compounds do not reach their site of action. One way to overcome this problem might be the fusion of these agents
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service